Laroprovstat

Intervention1 paper1 findingPubChem 154653847

Outcomes

1

LDL-C

downin humans1−51%

1 study

Laroprovstat decreases LDL-C in humans (up to 51%).
Review
Oral PCSK9 inhibitors: closing the gap between potency and practicality · Current opinion in lipidology · 18 Sep 2026

Latest

3

Current Opinion in LipidologyReview18 Sep

Oral PCSK9 inhibitors: closing the gap between potency and practicality

AHA Scientific Sessions 2025 AbstractHuman trial3 Nov

Laroprovstat (AZD0780) an oral, small molecule PCSK9 inhibitor demonstrates improvements in the lipid profile in participants with hypercholesterolemia: Results from a Phase 1 study

AHA Scientific Sessions 2025 AbstractIn silico3 Nov

Model-Based Evaluation of LDL-C Lowering for Laroprovstat (AZD0780), An Oral Small Molecule PCSK9 Inhibitor, and Rosuvastatin